Home > Research > Publications & Outputs > Immunogenicity and Protective Efficacy of an In...

Links

Text available via DOI:

View graph of relations

Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2. / Park, Jun-Gyu; Oladunni, Fatai S.; Rohaim, Mohammed A. et al.

In: iScience, Vol. 24, No. 9, 102941, 30.09.2021.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Park, J-G, Oladunni, FS, Rohaim, MA, Whittingham-Dowd, J, Tollitt, J, Hodges, MDJ, Fathallah, N, Assas, MB, Alhazmi, W, Almilaibary, A, Iqbal, M, Chang, P, Escalona, R, Shivanna, V, Torrelles, JB, Worthington, JJ, Jackson-Jones, LH, Martinez-Sobrido, L & Munir, M 2021, 'Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2', iScience, vol. 24, no. 9, 102941. https://doi.org/10.1016/j.isci.2021.102941

APA

Park, J-G., Oladunni, F. S., Rohaim, M. A., Whittingham-Dowd, J., Tollitt, J., Hodges, M. D. J., Fathallah, N., Assas, M. B., Alhazmi, W., Almilaibary, A., Iqbal, M., Chang, P., Escalona, R., Shivanna, V., Torrelles, J. B., Worthington, J. J., Jackson-Jones, L. H., Martinez-Sobrido, L., & Munir, M. (2021). Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2. iScience, 24(9), [102941]. https://doi.org/10.1016/j.isci.2021.102941

Vancouver

Park J-G, Oladunni FS, Rohaim MA, Whittingham-Dowd J, Tollitt J, Hodges MDJ et al. Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2. iScience. 2021 Sep 30;24(9):102941. Epub 2021 Aug 4. doi: 10.1016/j.isci.2021.102941

Author

Park, Jun-Gyu ; Oladunni, Fatai S. ; Rohaim, Mohammed A. et al. / Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2. In: iScience. 2021 ; Vol. 24, No. 9.

Bibtex

@article{0ae254ae4fae4ea7b7d8a3c0b4c120d9,
title = "Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2",
abstract = "SUMMARY Global deployment of an effective and safe vaccine is necessary to curtail the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based vectored-vaccine in mice and hamsters for its immunogenicity, safety and protective efficacy against SARS-CoV-2. Intranasal administration of recombinant (r)NDV-S vaccine expressing spike (S) protein of SARS-CoV-2 to mice induced high levels of SARS-CoV-2-specific neutralizing immunoglobulin A (IgA) and IgG2a antibodies and T cell-mediated immunity. Hamsters immunised with two doses of vaccine showed complete protection from lung infection, inflammation, and pathological lesions following SARS-CoV-2 challenge. Importantly, administration of two doses of intranasal rNDV-S vaccine significantly reduced the SARS-CoV-2 shedding in nasal turbinate and lungs in hamsters. Collectively, intranasal vaccination has the potential to control infection at the site of inoculation, which should prevent both clinical disease and virus transmission to halt the spread of the COVID-19 pandemic.",
keywords = "Vaccines, SARS-CoV-2, COVID-19, Pandemic, Viral Infection, Immunity",
author = "Jun-Gyu Park and Oladunni, {Fatai S.} and Rohaim, {Mohammed A.} and Jayde Whittingham-Dowd and James Tollitt and Hodges, {Matthew D.J.} and Nadin Fathallah and Assas, {Muhsref Bakri} and Wafaa Alhazmi and Abdullah Almilaibary and Munir Iqbal and Pengxiang Chang and Renee Escalona and Vinay Shivanna and Torrelles, {Jordi B.} and Worthington, {John J.} and Jackson-Jones, {Lucy H.} and Luis Martinez-Sobrido and Muhammad Munir",
year = "2021",
month = sep,
day = "30",
doi = "10.1016/j.isci.2021.102941",
language = "English",
volume = "24",
journal = "iScience",
issn = "2589-0042",
publisher = "Elsevier Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2

AU - Park, Jun-Gyu

AU - Oladunni, Fatai S.

AU - Rohaim, Mohammed A.

AU - Whittingham-Dowd, Jayde

AU - Tollitt, James

AU - Hodges, Matthew D.J.

AU - Fathallah, Nadin

AU - Assas, Muhsref Bakri

AU - Alhazmi, Wafaa

AU - Almilaibary, Abdullah

AU - Iqbal, Munir

AU - Chang, Pengxiang

AU - Escalona, Renee

AU - Shivanna, Vinay

AU - Torrelles, Jordi B.

AU - Worthington, John J.

AU - Jackson-Jones, Lucy H.

AU - Martinez-Sobrido, Luis

AU - Munir, Muhammad

PY - 2021/9/30

Y1 - 2021/9/30

N2 - SUMMARY Global deployment of an effective and safe vaccine is necessary to curtail the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based vectored-vaccine in mice and hamsters for its immunogenicity, safety and protective efficacy against SARS-CoV-2. Intranasal administration of recombinant (r)NDV-S vaccine expressing spike (S) protein of SARS-CoV-2 to mice induced high levels of SARS-CoV-2-specific neutralizing immunoglobulin A (IgA) and IgG2a antibodies and T cell-mediated immunity. Hamsters immunised with two doses of vaccine showed complete protection from lung infection, inflammation, and pathological lesions following SARS-CoV-2 challenge. Importantly, administration of two doses of intranasal rNDV-S vaccine significantly reduced the SARS-CoV-2 shedding in nasal turbinate and lungs in hamsters. Collectively, intranasal vaccination has the potential to control infection at the site of inoculation, which should prevent both clinical disease and virus transmission to halt the spread of the COVID-19 pandemic.

AB - SUMMARY Global deployment of an effective and safe vaccine is necessary to curtail the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we evaluated a Newcastle disease virus (NDV)-based vectored-vaccine in mice and hamsters for its immunogenicity, safety and protective efficacy against SARS-CoV-2. Intranasal administration of recombinant (r)NDV-S vaccine expressing spike (S) protein of SARS-CoV-2 to mice induced high levels of SARS-CoV-2-specific neutralizing immunoglobulin A (IgA) and IgG2a antibodies and T cell-mediated immunity. Hamsters immunised with two doses of vaccine showed complete protection from lung infection, inflammation, and pathological lesions following SARS-CoV-2 challenge. Importantly, administration of two doses of intranasal rNDV-S vaccine significantly reduced the SARS-CoV-2 shedding in nasal turbinate and lungs in hamsters. Collectively, intranasal vaccination has the potential to control infection at the site of inoculation, which should prevent both clinical disease and virus transmission to halt the spread of the COVID-19 pandemic.

KW - Vaccines

KW - SARS-CoV-2

KW - COVID-19

KW - Pandemic

KW - Viral Infection

KW - Immunity

U2 - 10.1016/j.isci.2021.102941

DO - 10.1016/j.isci.2021.102941

M3 - Journal article

VL - 24

JO - iScience

JF - iScience

SN - 2589-0042

IS - 9

M1 - 102941

ER -